Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824906 | 0.90 | BRD4 (0.43) | BRD4HDAC1HDAC6 | |
| SCHEMBL30812303 | 0.84 | BRD4 (0.45) | BRD4HDAC1HDAC6 | |
| SCHEMBL30812284 | 0.84 | BRD4 (0.46) | BRD4HDAC1HDAC6 | |
| SCHEMBL30812154 | 0.82 | BRD4 (0.41) | BRD4HDAC1HDAC6HTR6 | |
| SCHEMBL30812019 | 0.81 | BRD4 (0.41) | BRD4HDAC1HDAC6HTR6 | |
| SCHEMBL31245971 | 0.81 | BRD4 (0.48) | BRD4 | |
| SCHEMBL30812323 | 0.80 | BRD4 (0.44) | BRD4HDAC1HDAC6 | |
| SCHEMBL30812177 | 0.80 | BRD4 (0.43) | BRD4HDAC1HDAC6 | |
| SCHEMBL30812157 | 0.80 | BRD4 (0.52) | BRD4HTR6 | |
| SCHEMBL30824888 | 0.78 | BRD4 (0.52) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702022-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | Halda Therapeutics Opco, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260028338-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024211684-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028338-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS | BRD4 479/4885HDAC1 233/4885HDAC6 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.